Division of Dermatology, Department of Medicine, Washington University in St. Louis School of Medicine, St. Louis, MO, USA.
Center for Pharmacogenomics, Department of Medicine, Washington University in St. Louis School of Medicine, St. Louis, MO, USA.
Exp Dermatol. 2021 Aug;30(8):1150-1155. doi: 10.1111/exd.14392. Epub 2021 Jun 1.
Atopic dermatitis (AD) is an inflammatory skin disorder affecting up to 20% of the paediatric population worldwide. AD patients commonly exhibit dry skin and pruritus and are at a higher risk for developing asthma as well as allergic rhinitis. Filaggrin loss-of-function variants are the most widely replicated genetic risk factor among >40 genes associated with AD susceptibility. The prevalence of AD has tripled in the past 30 years in industrial countries around the world. This urgent public health issue has prompted the field to more thoroughly investigate the mechanisms that underlie AD pathogenesis amidst environmental exposures. Epigenetics is the study of heritable, yet reversible, modifications to the genome that affect gene expression. The past decade has seen an emergence of exciting studies identifying a role for epigenetic regulation associated with AD and at the interface of environmental factors. Such epigenetic studies have been empowered by sequencing technologies and human genome variation and epigenome maps. miRNAs that post-transcriptionally modify gene expression and circRNAs have also been discovered to be associated with AD. Here, we review our current understanding of epigenetics associated with atopic dermatitis. We discuss studies identifying distinct DNA methylation changes in keratinocytes and T cells, eQTLs as DNA methylation switches that impact gene expression, and histone modification changes associated with AD-related microbial dysbiosis. We further highlight the need for integrative and collaborative analyses to elucidate the impact of these epigenetic findings as potential drivers for AD pathogenesis and the translation of this new knowledge to develop newer targeted treatments.
特应性皮炎(AD)是一种炎症性皮肤疾病,影响全球多达 20%的儿童人群。AD 患者通常表现为皮肤干燥和瘙痒,并且患哮喘和过敏性鼻炎的风险更高。丝聚蛋白功能丧失变异是与 AD 易感性相关的 >40 个基因中最广泛复制的遗传风险因素。在过去的 30 年中,在世界范围内的工业化国家,AD 的患病率增加了两倍。这一紧迫的公共卫生问题促使该领域更深入地研究在环境暴露下导致 AD 发病机制的机制。表观遗传学是研究遗传但可逆转的基因组修饰,这些修饰会影响基因表达。在过去的十年中,令人兴奋的研究发现了与 AD 相关的表观遗传调控作用,以及与环境因素的相互作用。这些表观遗传学研究得益于测序技术和人类基因组变异和表观基因组图谱。还发现了 miRNA 可以在后转录水平修饰基因表达,circRNA 也与 AD 相关。在这里,我们回顾了我们对与特应性皮炎相关的表观遗传学的现有认识。我们讨论了在角质形成细胞和 T 细胞中识别出的独特 DNA 甲基化变化、作为 DNA 甲基化开关影响基因表达的 eQTLs ,以及与 AD 相关的微生物失调相关的组蛋白修饰变化。我们进一步强调了需要进行综合和协作分析,以阐明这些表观遗传学发现作为 AD 发病机制的潜在驱动因素的影响,并将这一新知识转化为开发新的靶向治疗方法。